Medicilon IncMedicilon IncMedicilon IncMedicilon Inc
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
    • Integrated Projects
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Our Events
    • Market Activity
    • Press Events
  • Contact

Thermal Protein Profiling May Provide New Insights on Antibiotic Resistance

Home Press Events
NextPrevious

Thermal Protein Profiling May Provide New Insights on Antibiotic Resistance

By medicilon | Press Events | 11 July, 2018 |

Scientists from the European Molecular Biology Laboratory (EMBL) say they have adapted an existing technique to study the melting behavior of proteins so that it can be used for the study of bacteria. Antibiotic resistance is spreading worldwide so there is a strong need for new technologies to study bacteria, according to the researchers who published their study (“Thermal proteome profiling in bacteria: probing protein state in vivo”) in Molecular Systems Biology.

 

“We adapted thermal proteome profiling (TPP) to probe the thermostability of Escherichia coli proteins in vivo. E. coli had a more thermostable proteome than human cells, with protein thermostability depending on subcellular location—forming a high-to-low gradient from the cell surface to the cytoplasm. While subunits of protein complexes residing in one compartment melted similarly, protein complexes spanning compartments often had their subunits melting in a location-wise manner. Monitoring the E. coli meltome and proteome at different growth phases captured changes in metabolism. Cells lacking TolC, a component of multiple efflux pumps, exhibited major physiological changes, including differential thermostability and levels of its interaction partners, signaling cascades, and periplasmic quality control,” write the investigators.

 

 

“Finally, we combined in vitro and in vivo TPP to identify targets of known antimicrobial drugs and to map their downstream effects. In conclusion, we demonstrate that TPP can be used in bacteria to probe protein complex architecture, metabolic pathways, and intracellular drug target engagement.”

 

TPP enables scientists to compare the melting behavior of all proteins in a cell or organism before and after a perturbation, such as the administration of a drug. By adapting TPP to bacteria, it can now be used to study the activity and architecture of most proteins in a bacterial cell while it’s alive, notes André Mateus, Ph.D., a postdoc working in the Savitski and Typas groups at EMBL.

 

While human bodies cease to function at temperatures above 42°C, E. coli bacteria still grow regularly up to 45°C. “We discovered that proteins in the middle of a bacterial cell are less tolerant to heat than those at the cell surface,” says Mikhail Savitski, Ph.D., team leader and head of proteomics core facility, EMBL. “Surprisingly, a protein’s location is more predictive for its melting behavior than which other proteins it interacts with.”

 

With TPP, researchers can also investigate the effects of drugs on bacteria. Protein-drug interactions typically increase the proteins’ heat tolerance, resulting in higher melting points. Therefore, comparing the heat tolerance of drug-treated and untreated bacterial cells helps to identify targets of antimicrobial drugs, but also to decipher how the bacterial cell succumbs to the drug or tries to bypass its action.

 

“In one particular case, we were able to elucidate a novel drug resistance mechanism,” says Dr. Mateus. “Cells use proteins to pump antibiotics out of the cell. After genetically removing one such efflux pump from their chromosome, bacteria became more sensitive to many drugs but curiously more resistant to one specific antibiotic called aztreonam. Using TPP, we found that this was due to dramatically reduced levels of a specific porin – a protein that acts as a pore – used by aztreonam to enter the cell.”

 

Compared to other techniques, TPP allows scientists to investigate the effects of perturbations on thousands of individual proteins in a short timeframe, explain the EMBL researchers. Most of the obtained insights – like the changes in the activity of proteins in vivo – would be impossible with other conventional techniques and for so many proteins simultaneously, showing TPP’s potential to study bacteria in detail, according to the scientists.

No tags.

Related Post

  • Happy Chinese New Year from Medicilon!

    Read more

  • Medicilon held the Preclincial and IND Declaration Seminar in Chengdu, China

    Medicilon held the Preclincial and IND Declaration Seminar in Chengdu, China. Medicilon CEO Chun-Lin Chen gaveRead more

  • Warmest Holiday Season Greeting From Medicilon!

    Dear Clients, Collaborative Partners and Friends, As the end of year is approaching, we would likeRead more

  • Improved Humanized Mice Enhance Vaccine Development

    Every animal model of disease comes with its own unique set of drawbacks. Yet, scientists continuallyRead more

  • Cancer Drug Discovery Gets Boost from Novel Proteomics Platform

    Scientists at the Van Andel Research Institute have developed a novel biochemical platform to research aRead more

  • Staph Genes That Turn Commensal to Killer Identified

    Don’t be alarmed, but a bacterium that could turn deadly is on your skin right now.Read more

  • Method Predicts Exact Mutations CRISPR Gene Editing Can Introduce into a Cell

    The largest study of CRISPR action to date has developed a method to predict the exactRead more

  • Two-Pronged Approach Shows Promise against Drug-Resistant Cancers

    Researchers at the University of California, San Francisco (UCSF) report that they have discovered why someRead more

NextPrevious

News

  • Our Events
  • Market Activity
  • Press Events

Tags

Bio-forum (1) Cooperation (1) Experience (1) Strategy (1)

Top Posts

  • 14 February, 2017

    IND Enabling Studies FDA

  • 14 August, 2017

    Factors Affecting Pharmacokinetics of Drugs

  • 14 October, 2016

    Preclinical Drug Development Process

  • 7 February, 2017

    Target Identification and Validation in Drug Discovery

Share

About Us

  • Medicilon Overview
  • Executive Team
  • CEO Message
  • Company History
  • Corporate Culture
  • Honor

Services

  • Chemistry Services
  • Biology Services
  • Bioanalytical Services
  • Drug Safety Evaluation
  • Formulation Development Services
  • Pharmacology Services
  • Pharmacokinetic Services
  • Integrated Projects

Customer Center

  • Customer Reviews
  • Download Center
  • Intellectual Property Protection
  • New Models of Collaboration

Contact Us

Shanghai Medicilon Inc.
Email: Marketing@medicilon.com.cn
Website: www.medicilon.com

Copyright 2017 Shanghai Medicilon inc. | All Rights Reserved
  • Languages
  • 中国日本대한민국
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
    • Integrated Projects
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Our Events
    • Market Activity
    • Press Events
  • Contact
Medicilon Inc